Axon Enterprise, Inc $AXON Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB trimmed its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 3.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,103 shares of the biotechnology company’s stock after selling 284 shares during the period. Nordea Investment Management AB’s holdings in Axon Enterprise were worth $7,476,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. LaSalle St. Investment Advisors LLC increased its position in shares of Axon Enterprise by 2.1% in the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 16 shares during the last quarter. Hemington Wealth Management increased its position in shares of Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 17 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Axon Enterprise by 5.0% in the 1st quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 18 shares during the last quarter. Kentucky Retirement Systems increased its position in shares of Axon Enterprise by 0.4% in the 1st quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company’s stock worth $2,605,000 after purchasing an additional 19 shares during the last quarter. Finally, WCM Investment Management LLC increased its position in shares of Axon Enterprise by 0.8% in the 1st quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company’s stock worth $1,306,000 after purchasing an additional 19 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 1.9%

NASDAQ AXON opened at $683.13 on Tuesday. Axon Enterprise, Inc has a one year low of $422.38 and a one year high of $885.91. The company has a 50-day simple moving average of $736.73 and a 200-day simple moving average of $720.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm has a market capitalization of $53.63 billion, a PE ratio of 168.67, a price-to-earnings-growth ratio of 26.04 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s revenue was up 32.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analysts Set New Price Targets

AXON has been the subject of several research analyst reports. Raymond James Financial reissued an “outperform” rating and issued a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. JPMorgan Chase & Co. boosted their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research report on Thursday, July 17th. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. UBS Group reaffirmed a “neutral” rating and issued a $840.00 price target (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a report on Wednesday, September 24th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus target price of $841.64.

Insider Activity

In other news, Director Hadi Partovi bought 1,358 shares of Axon Enterprise stock in a transaction on Wednesday, August 13th. The stock was purchased at an average cost of $740.00 per share, with a total value of $1,004,920.00. Following the purchase, the director directly owned 237,938 shares of the company’s stock, valued at approximately $176,074,120. This trade represents a 0.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Brittany Bagley sold 5,000 shares of the business’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the transaction, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at $66,813,456.96. The trade was a 5.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,932 shares of company stock worth $45,115,616 over the last three months. Insiders own 5.70% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.